Saxon Interests Inc. Has $1.83 Million Stock Holdings in AbbVie Inc. $ABBV

Saxon Interests Inc. grew its stake in AbbVie Inc. (NYSE:ABBV) by 126.9% during the third quarter, HoldingsChannel.com reports. The firm owned 7,908 shares of the company’s stock after buying an additional 4,423 shares during the period. Saxon Interests Inc.’s holdings in AbbVie were worth $1,831,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Ellenbecker Investment Group lifted its stake in AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after buying an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA increased its stake in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after acquiring an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC raised its position in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after acquiring an additional 45 shares during the period. Centennial Wealth Advisory LLC raised its position in shares of AbbVie by 2.2% in the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after acquiring an additional 45 shares during the period. Finally, Willner & Heller LLC boosted its stake in AbbVie by 0.6% during the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after acquiring an additional 46 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $220.55 on Tuesday. The stock has a 50-day simple moving average of $225.33 and a 200 day simple moving average of $217.78. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a market cap of $389.80 billion, a PE ratio of 167.09, a PEG ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Citigroup lowered their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, Morgan Stanley lifted their price objective on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $248.11.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.